ClinicalTrials.gg
CompletedNCT02944474Updated May 2, 2025

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy Subjects

A Phase 1 interventional study of Lucerastat and Placebo in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The objectives of this study were to evaluate the safety and tolerability of lucerastat and to determine its pharmacokinetic profile after multiple dosing. Also, the potential effect of food on the pharmacokinetics of lucerastat was explored following a single dose of 500 mg.

Read the detailed description

The subjects were to be enrolled sequentially to three dose groups, starting with the lowest dose level. Subjects could participate in only one Group. Progression to an increased dose of lucerastat was permitted only after review of all data from the previous cohort suggested that it was safe to do so.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Pharmacokinetics
  • Safety
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form.
  • Male subjects aged from 18 to 45 years at screening.
  • Body weight between 50 and 100 kg and (BMI) between 18.0 and 29.0 kg/m2 at screening.
  • Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • History or clinical evidence of any disease or medical / surgical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study treatments.
  • Serious adverse reaction or to any drug.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Cohort 1 (200 mg)

    Six subjects received 200 mg of lucerastat twice daily for 7 consecutive days in fasting conditions

    Drug: Lucerastat

  • Experimental
    Cohort 2 (500 mg)

    Six subjects received 500 mg of lucerastat as a single dose in the morning of Day 1 in fed conditions. After a 5-day washout, they received the same dose twice daily for 7 consecutive days in fasting conditions

    Drug: Lucerastat

  • Experimental
    Cohort 3 (500 mg)

    Six subjects received 500 mg of lucerastat twice daily for 7 consecutive days in fasting conditions

    Drug: Lucerastat

  • Experimental
    Cohort 4 (1000 mg)

    Six subjects received 1 g of lucerastat for 7 consecutive days in fasting conditions

    Drug: Lucerastat

  • Placebo comparator
    Placebo cohorts 1 to 4

    Twelve subjects received matched placebo (3 subjects per cohort, except for Cohort 3 where 4 subjects received placebo)

    Drug: Placebo

Interventions

  • Capsule for oral administration containing lucerastat

    Also known as: OGT-923, ACT-434964, CDP923

  • DrugPlacebo

    Placebo capsules matching lucerastat capsules

06

What researchers measure

Primary outcomes

  1. Dose proportionality in lucerastat pharmacokinetics assessed by maximum plasma concentration (Cmax)

    Cmax was used to assess dose proportionality across all dose groups

    Time frame: PK blood samples were collected on Day 7, at pre-dose and at scheduled time points up to 48 hours after the morning dose

  2. Dose proportionality in lucerastat pharmacokinetics assessed by area under the concentration-time curve (AUC)

    AUC from time zero to infinity \[AUC(0-inf)\] was used to assess dose proportionality across all dose groups

    Time frame: PK blood samples were collected on Day 7, at pre-dose and at scheduled time points up to 48 hours after the morning dose on Day 7

  3. Terminal elimination half-life (t1/2)

    t1/2 was calculated from the plasma concentrations-time curves of lucerastat after multiple doses

    Time frame: PK blood samples were collected on Day 7, at pre-dose and at scheduled time points up to 48 hours after the morning dose on Day 7

  4. Food effect on lucerastat pharmacokinetics assessed by Cmax

    Potential food effect on pharmacokinetic parameters of lucerastat was tested by comparing Cmax in fed vs fasted state in the 500 mg cohort (cohort 2)

    Time frame: PK blood samples were collected on Day 1, at pre-dose and at scheduled time points up to 12 hours after the morning dose

  5. Food effect on lucerastat pharmacokinetics assessed by AUC

    Potential food effect on pharmacokinetic parameters of lucerastat was tested by comparing AUC in fed versus fasted state in the 500 mg cohort (cohort 2)

    Time frame: PK blood samples were collected on Day 1, at pre-dose and at scheduled time points up to 12 hours after the morning dose

  6. Number of participants with adverse events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation subject, which did not necessarily have a causal relationship with the treatment

    Time frame: From baseline up to Day 14 (end of study)

  7. Change from baseline in haematology after multiple doses of lucerastat

    Time frame: Up to Day 9

  8. Change from baseline in clinical chemistry after multiple doses of lucerastat

    Time frame: Up to Day 9

  9. Change from baseline in heart rate after multiple doses of lucerastat

    Time frame: Up to Day 9

Secondary outcomes

  1. Change from baseline in haematology after a single dose of lucerastat

    Time frame: At 24 hours post dose

  2. Change from baseline in clinical chemistry after a single dose of lucerastat

    Time frame: At 24 hours post dose

  3. Change from baseline in heart rate after a single dose of lucerastat

    Time frame: At 24 hours post dose

  4. Change from baseline in blood pressure after a single dose of lucerastat

    Time frame: Up to 24 hours post dose

  5. Change from baseline in electrocardiogram (ECG) variables after a single dose of lucerastat

    Time frame: Up to 24 hours post dose

  6. Stool frequency after multiple doses of lucerastat

    Time frame: Every day up to Day 9

  7. Change from baseline in body weight after multiple doses of lucerastat

    Time frame: At Day 9

07

Study locations

1 site
  • Investigator Site
    Edinburgh, EH14 4AP, United Kingdom
08

References and documents

Publications

  • Guerard N, Morand O, Dingemanse J. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J Rare Dis. 2017 Jan 14;12(1):9. doi: 10.1186/s13023-017-0565-9. PubMed 28088251 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of May 2004 and a completion of May 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2016
First posted
Oct 26, 2016
Start
Dec 2003
Primary completionActual
May 2004
CompletionActual
May 2004
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02944474
Responsible party
Sponsor
First posted
Oct 26, 2016
Start date
Dec 2003
Primary completion
May 2004
Completion
May 2004
Last update
May 2, 2025

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion